ALX Oncology Holdings ALXO 深 滬
等待開盤 11-04 09:30:00 美东时间
1.57
+0.030
+1.95%
華盛通- 最 高1.64
- 今 開1.57
- 成交量 16.60万股
- 最 低 1.54
- 昨 收 1.54
- 總市值 8390.71万
- 52周最高 2.27
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 0.404
- 委 比 90.13%
- 總股本 5344.40万
- 歷史最高 117.45
- 量 比 0.77
- 振 幅 6.49%
- 歷史最低 0.404
- 每 手 1
- 風險率 0.50%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多ALX Oncology Presents Preclinical Data And Trial Design For Ongoing Phase 1 Clinical Trial For ADC Candidate, ALX2004, In Two Poster Presentations At 2025 AACR-NCI-EORTC Conference
-Two poster presentations showcase best- and first-in-class potential of ALX2004, a novel, antibody-drug conjugate (ADC) for the treatment of EGFR-expressing solid tumors-Robust body of preclinical data supports ALX2004
10-24 00:31
ALX Oncology Announces Preclinical Data and Phase 1 Trial-in-Progress Presentations of ALX2004, a Novel EGFR-Targeted ADC, at 2025 AACR-NCI-EORTC Conference
ALX Oncology presented preclinical data and Phase 1 trial design for its novel ADC, ALX2004, targeting EGFR-expressing solid tumors, at the 2025 AACR-NCI-EORTC Conference. ALX2004 demonstrates potent anti-tumor activity and a favorable safety profile, addressing limitations of earlier ADCs. Initial safety data from the first-in-human trial is expected in early 2026. The company highlighted ALX2004's unique design, including a proprietary linker-p...
10-23 16:30
ALX Oncology to Present Updated Data from Phase 2 ASPEN-06 Trial, Highlighting CD47 Expression as a Predictive Biomarker in HER2+ Gastric Cancer, at 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting
ALX Oncology will present updated Phase 2 ASPEN-06 trial data at the SITC 2025 Annual Meeting, highlighting CD47 overexpression as a key predictive biomarker for response to evorpacept in HER2+ gastric cancer. The trial evaluates evorpacept in combination with HERCEPTIN, CYRAMZA, and paclitaxel for patients with previously treated HER2-positive advanced gastric or gastroesophageal junction cancer. The study enrolled 127 patients and aims to demon...
10-03 13:05
ALX Oncology Announces Management Changes Amidst Nasdaq Compliance
The latest update is out from ALX Oncology Holdings ( ($ALXO) ). On September 1...
09-12 20:57
ALX Oncology Appoints Board Member Barbara Klencke, M.D., as Interim Chief Medical Officer
ALX Oncology announced that Barbara Klencke, M.D., will serve as Interim Chief Medical Officer, while Alan Sandler, M.D., steps down from the role to return to the Board of Directors. Dr. Klencke, with over 30 years of experience in oncology drug development, will lead the Company’s clinical programs, including evorpacept and ALX2004.
09-12 12:30
ALX Oncology to Participate in Upcoming Investor Conferences in September
ALX Oncology's leadership will participate in two major conferences in September 2025: the Cantor Global Healthcare Conference featuring a fireside chat and one-on-one meetings on September 3, and the H.C. Wainwright Investment Conference focusing on one-on-one meetings on September 9. Both events will be held in New York. The webcast links and replay information are available on ALX Oncology’s website. The company, advancing novel cancer therapi...
08-29 16:00
Why Palo Alto Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Shares of Palo Alto Networks, Inc. (NASDAQ:PANW) rose sharply in pre-market tra...
08-19 20:01
ALX Oncology Doses First Patient in Phase 1 Dose Escalation Trial Evaluating ADC ALX2004 for the Treatment of EGFR-Expressing Solid Tumors
ALX Oncology has initiated a Phase 1 clinical trial for its novel EGFR-targeted ADC, ALX2004, designed to treat EGFR-expressing solid tumors. The trial aims to evaluate safety and efficacy, with initial data expected in H1 2026. ALX2004 features an optimized antibody, linker, and payload to enhance therapeutic potential and reduce toxicity, building on promising preclinical results showing dose-dependent anti-tumor activity and a favorable safety...
08-19 12:00
ALX Oncology Appoints Dr. Curran to Board
An announcement from ALX Oncology Holdings ( ($ALXO) ) is now available. On Aug...
08-13 04:50
ALX Oncology Reports Second Quarter 2025 Financial Results and Provides Corporate Update
ALX Oncology reported Q2 2025 financial results and corporate updates, highlighting advancements in their evorpacept and ALX2004 clinical programs. CD47 expression emerged as a key predictive biomarker for evorpacept response in HER2+ gastric cancer, with updated ASPEN-Breast trial design focusing on biomarker-driven strategies. The Phase 1 trial for ALX2004 remains on track, with first patient dosing expected in August. The company extended its ...
08-12 20:05
